Your participation in the STRIVE Study is bringing Henry Ford Health System, GRAIL, and its collaborators one step closer to developing an important new tool to detect cancer early. Thank you for completing the first phase of your STRIVE Study participation. Your continued engagement in the follow-up phase will help with the ongoing development of the GRAIL blood test.
The success of the STRIVE Study depends on our ability to follow participants for cancer events over time. This follow-up is critical to the development of a blood test for the early detection of cancer. The STRIVE Study team will be reaching out to participants occasionally to collect study follow-up information. Additionally, study researchers will also be actively monitoring electronic health records for up to 5 years from enrollment to capture clinical outcome data, including cancer diagnoses.
Keeping your contact information up to date is very important so that the study team at your health center can reach you during the follow-up period. Please contact the study team by emailing STRIVE@hfhs.org or by calling 1-833-3-STRIVE (1-833-378-7483) if: